Journal of International Oncology››2023,Vol. 50››Issue (12): 763-765.doi:10.3760/cma.j.cn371439-20230510-00143
Previous ArticlesNext Articles
Received:2023-05-10Revised:2023-09-23Online:2023-12-08Published:2024-01-16
"
"
"
| [1] | Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer[J].Semin Oncol,2020,47(5): 259-269. DOI:10.1053/j.seminoncol.2020.07.008. pmid:32896428 |
| [2] | Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J].N Engl J Med,2011,365(14): 1273-1283. DOI:10.1056/NEJMoa0910383. |
| [3] | Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the north central cancer treatment group N9831 clinical trials[J].J Clin Oncol,2010,28(21): 3416-3421. DOI:10.1200/JCO.2009.23.6950. pmid:20530275 |
| [4] | Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J].J Clin Oncol,2014,32(33): 3744-3752. DOI:10.1200/JCO.2014.55.5730. pmid:25332249 |
| [5] | Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J].Lancet,2017,389(10075): 1195-1205. DOI:10.1016/S0140-6736(16)32616-2. pmid:28215665 |
| [6] | Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11): 783-792. DOI:10.1056/NEJM200103153441101. |
| [7] | Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J].J Clin Oncol,2005,23(19): 4265-4274. DOI:10.1200/JCO.2005.04.173. |
| [8] | Chen X, Wang J, Fan Y, et al. Primary trastuzumab resistance after (Neo) adjuvant trastuzumab-containing treatment for patients with HER2-positive breast cancer in real-world practice[J].Clin Breast Cancer,2021,21(3): 191-198. DOI:10.1016/j.clbc.2020.09.003. |
| [9] | 韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展[J].中华普通外科学文献(电子版),2021,15(6): 453-458. DOI:10.3877/cma.j.issn.1674-0793.2021.06.013. |
| [10] | 边莉, 徐兵河, 邸立军, 等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J].中华医学杂志,2020,100(30): 2351-2357. DOI:10.3760/cma.j.cn112137-20200116-00105. |
| [11] | Tao W, Zhang P, Di L, et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study[J].Transl Breast Cancer Res,2022,3: 15. DOI:10.21037/tbcr-21-42. |
| [12] | Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲ randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study[J].J Clin Oncol,2011,29(3): 264-271. DOI:10.1200/JCO.2010.30.8213. pmid:21149659 |
| [13] | Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J].Lancet Oncol,2021,22(3): 351-360. DOI:10.1016/S1470-2045(20)30702-6. pmid:33581774 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
